Abstracts Archive - Page 1065 of 2607 - ACR Meeting Abstracts

Abstract Number: 1873 • 2019 ACR/ARP Annual Meeting
Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
Thomas Olenginski¹ and Karen Mackiewicz ², ¹Geisinger Medical Center, Danville, PA, ²Geisinger, Danville, PA
Background/Purpose: The morbidity and mortality of osteoporotic fractures threaten our aging population. Despite advances in new therapies for osteoporosis and technology to more effectively communicate, fewer…
Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Erik Eriksen¹, Roland Chapurlat ², Rogely Boyce ³, Jacques Brown ⁴, Stéphane Horlait ⁵, Cesar Libanati ⁶, Yifei Shi ³, Rachel Wagman ³ and Pascale Chavassieux ², ¹Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, ²INSERM UMR 1033, Université de Lyon, Lyon, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ⁵Amgen Inc., Boulogne Billancourt, France, ⁶UCB Pharma, Brussels, Belgium
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
Abstract Number: 1875 • 2019 ACR/ARP Annual Meeting
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
David Kendler¹, Arkadi Chines ², Patricia Clark ³, Peter R. Ebeling ⁴, Michael McClung ⁵, Yumie Rhee ⁶, Shuang Huang ², Robert Kees Stad ⁷ and Nick Freemantle ⁸, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, ⁴Monash University, Melbourne, Victoria, Australia, ⁵Oregon Osteoporosis Center, Portland, OR, ⁶Yonsei University College of Medicine, Seoul, Republic of Korea, ⁷Amgen Inc., Rotkreuz, Zug, Switzerland, ⁸University College London, London, England, United Kingdom
Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…
Abstract Number: 1876 • 2019 ACR/ARP Annual Meeting
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Kenneth Saag¹, Michele McDermott ², Jonathan Adachi ³, Willem Lems ⁴, Nancy Lane ⁵, Piet Geusens ⁶, Peter Butler ², Li Chen ², Daria Crittenden ², Robin Dore ⁷ and Stanley Cohen ⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University and St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴VU University Medical Centre, Amsterdam, Netherlands, ⁵University of California at Davis Medical Center, Sacramento, CA, ⁶Maastricht University, Maastricht, Netherlands, ⁷Robin K Dore Inc, Tustin, CA, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…
Abstract Number: 1877 • 2019 ACR/ARP Annual Meeting
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Jacques Brown¹, Arkadi Chines ², Roland Chapurlat ³, Joseph Foldes ⁴, Xavier Nogues ⁵, Roberto Civitelli ⁶, Tobias De Villiers ⁷, Fabio Massari ⁸, Cristiano A. Zerbini ⁹, Wenjing Yang ², Chris Recknor ¹⁰ and Cesar Libanati ¹¹, ¹CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³INSERM UMR 1033, Université de Lyon, Lyon, France, ⁴Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁵IMIM Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Stellenbosch University, Stellenbosch, South Africa, ⁸Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, ⁹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹⁰United Osteoporosis Centers, Gainesville, GA, ¹¹UCB Pharma, Brussels, Belgium
Background/Purpose: Recent evidence suggests BMD achieved during treatment is a reliable surrogate for fracture risk reduction (Bouxsein JBMR 2019). Romosozumab (Romo) is a bone-forming agent…
Abstract Number: 1878 • 2019 ACR/ARP Annual Meeting
Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice
Sebastian Rodriguez-Garcia¹, Raul Castellanos-Moreira ², Jacqueline Uson-Jaeger ³, ESPERANZA NAREDO ⁴ and Loreto Carmona ⁵, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ³Hospital Universitario de Mostoles, Madrid, Spain, ⁴Rheumatology Department, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma, MADRID, Spain, ⁵Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain
Background/Purpose: In recent years, diverse compounds for intra-articular (IA) administration were brought into the market with a subsequent significant and heterogeneous literature production. Understanding the efficacy…
Abstract Number: 1879 • 2019 ACR/ARP Annual Meeting
The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Lisa Carlesso¹, Laura Frey Law ², Na Wang ³, Michael Nevitt ⁴, Beth Lewis ⁵ and Tuhina Neogi ³, ¹McMaster University, Hamilton, ON, Canada, ²University of Iowa, Iowa City, IA, ³Boston University School of Medicine, Boston, MA, ⁴University of California at San Francisco, San Francisco, CA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Intermittent pain progresses to constant pain in some, but not all, individuals with knee osteoarthritis (OA). Differing pain mechanisms may underlie these transitions. Later…
Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Janet Pope¹, Yvonne Lee ², Jeffrey Curtis ³, Daojun Mo ⁴, Terence Rooney ⁴, Li Xie ⁴, Christina Dickson ⁴, Douglas Schlichting ⁴, Amanda Quebe ⁴, Anabela Cardoso ⁴, Lee Simon ⁵ and Peter Taylor ⁶, ¹Western University, London, ON, Canada, ²Northwestern University Feinberg School of Medicine, Chicago, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵SDG LLC, Cambridge, MA, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
Abstract Number: 1881 • 2019 ACR/ARP Annual Meeting
Association of Pain Centralization with DMARD Response in Active RA
Andrew Heisler¹, Jing Song ², Dorothy Dunlop ¹, Alyssa Wohlfahrt ³, Marcy Bolster ⁴, Wendy Marder ⁵, Clifton Bingham ⁶, Daniel Clauw ⁷, Tuhina Neogi ⁸ and Yvonne Lee ⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Worthington, OH, ³Brigham and Woman's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ⁸Boston University School of Medicine, Boston, MA, ⁹Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Despite the availability of potent disease modifying anti-rheumatic drugs (DMARDs), a significant percentage of rheumatoid arthritis (RA) patients do not achieve low disease activity…
Abstract Number: 1882 • 2019 ACR/ARP Annual Meeting
Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis
Yoon Mun¹, Tuhina Neogi ², Jing Song ³, Dorothy Dunlop ¹, Andrew Heisler ¹, Marcy Bolster ⁴, Clifton Bingham ⁵, Wendy Marder ⁶, Alyssa Wohlfahrt ⁷ and Yvonne Lee ⁸, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Boston University School of Medicine, Boston, MA, ³Northwestern University Feinberg School of Medicine, Worthington, OH, ⁴Massachusetts General Hospital, Boston, MA, ⁵Johns Hopkins University, Baltimore, ⁶Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁷Brigham and Woman's Hospital, Boston, MA, ⁸Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Many patients with RA report persistent pain in the absence of clinically appreciable inflammation. In a mouse model of inflammatory arthritis, mice injected with…
Abstract Number: 1883 • 2019 ACR/ARP Annual Meeting
Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
Jaymin Upadhyay¹, Diana Sibai ¹, Robert Labadie ², Jordan Lemme ³, Christine Sieberg ², Kirsten Ecklund ⁴, David Borsook ⁴ and Robert Sundel ⁴, ¹Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Boston Children’s Hospital, Harvard Medical School, Boston, MA, ³Boston Children's Hospital, Harvard Medical School, Boston, ⁴Boston Children’s Hospital, Harvard Medical School, Boston
Background/Purpose: Despite a broad range of available therapeutics, pain remains poorly treated in many juvenile idiopathic arthritis (JIA) patients1-2. For some patients, the level of pain…
Abstract Number: 1884 • 2019 ACR/ARP Annual Meeting
Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis
Ted Mikuls¹, Jess Edison ², Elizabeth Mewshaw ², Harlan Sayles ³, Geoffrey Thiele ¹, Michael Duryee ³, Carlos Hunter ³, LauraKay Moss ⁴, Marie Feser ⁵, Mark Parish ⁶ and Kevin Deane ⁵, ¹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ²Walter Reed National Military Medical Center, Bethesda, MD, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁵University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁶University of Colorado Denver, Aurora, CO
Background/Purpose: Previous work has demonstrated that malondialdehyde-acetalehyde (MAA) adducts, resulting from oxidative stress, are formed in synovial and lung tissues of patients with rheumatoid arthritis…
Abstract Number: 1885 • 2019 ACR/ARP Annual Meeting
A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia
Xanthe ME Matthijssen¹, Fenne Wouters ², Debbie Boeters ², Aleid Boer ², Yousra Dakkak ², Ellis Niemantsverdriet ² and Annette van der Helm-van Mil ³, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Based on a unique cohort of clinically suspect arthralgia (CSA) patients, we analysed which combinations of MRI-features at onset were predictive for Rheumatoid Arthritis…
Abstract Number: 1886 • 2019 ACR/ARP Annual Meeting
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Thierry Dervieux¹, Joel Kremer ², John Conklin ¹, Kelley Brady ¹, Roberta Alexander ¹, Tyler O'Malley ³, Jing Shi ¹, Claudia Ibarra ¹, Michael Mahler ⁴, Michael Weinblatt ⁵ and Arthur Weinstein ¹, ¹Exagen, Vista, CA, ²Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY, ³Exagen, Oceanside, CA, ⁴Inova Diagnostics, San Diego, CA, ⁵Brigham and Women's Hospital, Boston, MA
Background/Purpose: Novel antibody systems including anti-carbamylated protein antibody (anti-CarP IgG) and anti-peptidyl arginine deiminase antibody (anti-PAD4 IgG) are emerging as independent diagnostic and prognostic biomarkers…
Abstract Number: 1887 • 2019 ACR/ARP Annual Meeting
Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
Richard Moore¹, Tiffany Pan ¹, J. Lee Nelson ² and Christian Lood ¹, ¹University of Washington, Seattle, ²Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Mitochondria are key regulators of metabolism, inflammation and cell death, with mitochondrial dysfunction being associated with several diseases. Though mainly found intracellularly, we recently…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].